25E-NBOH

25E-NBOH (2-(2,5-dimethoxy-4-ethylphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine) is a synthetic psychedelic phenethylamine of the NBOH series, structurally related to 2C-E through the addition of an N-(2-hydroxybenzyl) group on the terminal nitrogen. Like all NBOH compounds, it produces psychedelic effects through potent 5-HT2A agonism and is active only via sublingual or buccal administration.

25E-NBOH is among the less well-characterized compounds in the NBOH family. Published human data are limited, and much of what is known derives from structure-activity extrapolation from 2C-E and other NBOH analogs, combined with informal community experience reports. 2C-E is known to produce a particularly intense, demanding, and cognitively complex psychedelic experience — sometimes described as more "serious" and less recreational than 2C-B or 2C-C. Whether 25E-NBOH preserves this character profile is plausible but not definitively established.

The NBOH series is generally considered to carry less acute fatality risk than the corresponding NBOMe compounds. No confirmed fatalities from 25E-NBOH alone have been documented. However, the absence of documented fatalities reflects both pharmacological differences from NBOMe and the significantly lower prevalence of NBOH compounds in drug markets. The fundamental hazards of any potent psychedelic active at microgram doses with a steep dose-response curve — accurate dosing difficulty, vasoconstriction, cardiovascular effects, psychological risks — remain fully applicable.